Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
May 1st, 2007
Kosan Biosciences Incorporated (NASDAQ:KOSN) today presented safety data from preclinical and clinical studies of its lead Hsp90 inhibitor, tanespimycin (KOS-953). Serial electrocardiogram (ECG) monitoring of patients was conducted in four Phase 1 trials of tanespimycin. Cardiac monitoring analyses were conducted in more than 85 patients. Tanespimycin was found to have no effect on QTc interval (a measure of the heart's electrical cycle) in these patients based on data analyses from manually read ECGs in a central laboratory or by site cardiologists. "The analyses performed by cardiac specialists confirm that tanespimycin had no effect on QTc interval," said Robert G....
Source: Cancer Weekly (2007-05-01)
|
